Swiss Life Sciences Database

News in the Life Sciences Industry
Results 241 - 260 out of 307 displayed.
« 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 »

European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer

By: Nasdaq / GlobenewsWire - 29 Aug 2019

Related companies: F. Hoffmann-La Roche AG (Venture Fund) | Hoffmann-La Roche Limited (Roche Canada) | F. Hoffmann-La Roche AG | Hoffmann-La Roche Ltd. (Edmonton)

Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

By: Nasdaq / GlobenewsWire - 29 Aug 2019

Related companies: F. Hoffmann-La Roche AG (Venture Fund) | Hoffmann-La Roche Limited (Roche Canada) | F. Hoffmann-La Roche AG | Hoffmann-La Roche Ltd. (Edmonton)

Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9

By: Nasdaq / GlobenewsWire - 28 Aug 2019

InSphero human liver disease platform selected to test Cyclerion's sGC stimulator technology as potential therapeutic approach for NASH and fibrosis

SCHLIEREN, Switzerland, Aug. 27, 2019 /PRNewswire/ -- InSphero today announced that in a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at Cyclerion Therapeutics, a clinical stage biopharmaceutical company, used InSphero Read more ››

By: PR Newswire Association LLC. - 27 Aug 2019

Related companies: INSPHERO AG

Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer

By: Nasdaq / GlobenewsWire - 27 Aug 2019

Related companies: Basilea Pharmaceutica Ltd

Van Leeuwenhoeck Issues Equity Research Report with Strong Buy and Price Target of CHF11-12 per Share

By: Nasdaq / GlobenewsWire - 27 Aug 2019

Related companies: Addex Therapeutics S.A.

Novo Nordisk A/S – Share repurchase programme

By: Nasdaq / GlobenewsWire - 26 Aug 2019

Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs

By: Nasdaq / GlobenewsWire - 26 Aug 2019

Related companies: Auris Medical AG

Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019

By: Nasdaq / GlobenewsWire - 23 Aug 2019

Related companies: Idorsia Pharmaceuticals Ltd

Steward Health Care Signs Long-Term Agreement with B. Braun for IV Solutions and Infusion Pumps

By: Nasdaq / GlobenewsWire - 21 Aug 2019

Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months

By: Nasdaq / GlobenewsWire - 20 Aug 2019

Related companies: Genkyotex S.A.

Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019

By: Nasdaq / GlobenewsWire - 20 Aug 2019

Related companies: Basilea Pharmaceutica Ltd

Araris Biotech AG closes seed financing round of CHF 2.5 million

By: Nasdaq / GlobenewsWire - 20 Aug 2019

Related companies: Araris Biotech AG

Novo Nordisk A/S – Share repurchase programme

By: Nasdaq / GlobenewsWire - 19 Aug 2019

Sanofi: information concerning the total number of voting rights and shares, July 2019

By: Nasdaq / GlobenewsWire - 19 Aug 2019

Novo Nordisk A/S: Securities lawsuit filed in Denmark against Novo Nordisk

By: Nasdaq / GlobenewsWire - 16 Aug 2019

FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

By: Nasdaq / GlobenewsWire - 16 Aug 2019

Related companies: F. Hoffmann-La Roche AG (Venture Fund) | Hoffmann-La Roche Limited (Roche Canada) | F. Hoffmann-La Roche AG | Hoffmann-La Roche Ltd. (Edmonton)

Auris Medical Provides Business Update and Reports First Half 2019 Financial Results

By: Nasdaq / GlobenewsWire - 15 Aug 2019

Related companies: Auris Medical AG

B. Braun Successfully Integrates with Epic at Prime Healthcare – Huntington Beach Hospital

By: Nasdaq / GlobenewsWire - 15 Aug 2019

Immunovant Appoints Robert K. Zeldin, M.D. as Chief Medical Officer and W. Bradford Middlekauff, J.D. as General Counsel

NEW YORK and BASEL, Switzerland, Aug. 13, 2019 /PRNewswire/ -- Immunovant, a biopharmaceutical company focused on developing innovative therapies for patients living with debilitating autoimmune diseases, today announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer and... Read more ››

By: PR Newswire Association LLC. - 13 Aug 2019

« 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 »

Looking for companies outside of Switzerland?

Browse our global Life Sciences lead sourcing platform Biotechgate for company information, product pipelines, licensing opportunities, management details and much more.